SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Gautam Mehta, Rajeshwar P Mookerjee, Breaking Bad – the two sides of gut microbiota in portal hypertension, Liver International, 2014, 34, 9
  2. 2
    Annarosa Floreani, Irene Franceschet, Lisa Perini, Nora Cazzagon, M. Eric Gershwin, Christopher L. Bowlus, New Therapies for Primary Biliary Cirrhosis, Clinical Reviews in Allergy & Immunology, 2014,

    CrossRef

  3. You have free access to this content3
    Mariana V. Machado, Helena Cortez-Pinto, Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?, Liver International, 2014, 34, 9
  4. 4
    Kidist K Yimam, Christopher L Bowlus, Obeticholic acid for the treatment of primary biliary cirrhosis, Expert Opinion on Orphan Drugs, 2014, 1

    CrossRef

  5. 5
    Jordi Gracia-Sancho, Virginia Hernández-Gea, Juan Carlos Garcia-Pagán, Obeticholic acid: A new light in the shadows treating portal hypertension?, Hepatology, 2014, 59, 6
  6. 6
    Annalisa Berzigotti, Jaime Bosch, Pharmacologic Management of Portal Hypertension, Clinics in Liver Disease, 2014, 18, 2, 303

    CrossRef

  7. 7
    Yasuko Iwakiri, Vijay Shah, Don C. Rockey, Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions, Journal of Hepatology, 2014, 61, 4, 912

    CrossRef